[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology].
Thromboembolic events are still a major cause of morbidity and mortality in patients with native valvular heart disease and in patients with prosthetic heart valves. Although the introduction of oral anticoagulation reduced this risk, thromboembolism and anticoagulation-related hemorrhages still represent significant problems in the management of these patients. In this article the guidelines developed by the Working Group on Valvular Heart Disease of the European Society of Cardiology for the management of antithrombotic therapy in heart valve disease are thoroughly discussed. The indication for and intensity of anticoagulation in various clinical situations, the concept of risk factor-adjusted intensity of anticoagulation, and the concept of control of oral anticoagulation with the International Normalized Ratio are presented.
Gohlke-Bärwolf
C
C
Acar
J
J
Oakley
C
C
Butchart
E
E
Burckhardt
D
D
Delahaye
J P
JP
Horstkotte
D
D
Bodnar
E
E
Hall
R
R
Kremer
R
R
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006349:Heart Valve Diseases / Q000097:blood / Q000150:complications*; D006350:Heart Valve Prosthesis; D006801:Humans; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents
Empfehlungen zur Thromboembolieprophylaxe bei Herzklappenerkrankungen der Working Group on Valvular Heart Disease, European Society of Cardiology.